StockNews.com started coverage on shares of Intercept Pharmaceuticals ( NASDAQ:ICPT – Free Report ) in a research note issued to investors on Saturday morning. The brokerage issued a hold rating on the biopharmaceutical company's stock. A number of other research firms also recently weighed in on ICPT. B. Riley dropped their price target on shares of Intercept Pharmaceuticals from $30.00 to $15.00 in a research note on Tuesday, May 30th. Raymond James downgraded shares of Intercept Pharmaceuticals from an outperform rating to a market perform rating in a research report on Wednesday, May 17th.

https://www.dailypolitical.com/2023/08/20/intercept-pharmaceuticals-nasdaqicpt-receives-new-coverage-from-analysts-at-stocknews-com.html

#dailypolitical